Despegar.com (NYSE:DESP) 주식

Despegar.com

Despegar.com Corp is an online travel company in Latin America. Its product offering includes airline tickets, packages, hotels, and other travel-related products, which enables consumers to find, compare, plan, and purchase travel products easily. The company provides a technology platform for managing the distribution of products and providing access to users to the network of travel suppliers. It operates through three segments: Air, which consists of the sale of airline tickets; Packages, Hotels, and Other Travel Products, which consists of travel packages, as well as sales of hotel rooms, car rentals, bus tickets, cruise tickets, travel insurance, and destination services; and Financial Services. Its geographical segments are Argentina, Brazil, Uruguay, Mexico, and other countries.

Alibaba Group Holding Ltd. (BABA)

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

AMAT

BABA

DESP

금요일(15일) 아침 미국 주식 선물이 하락세를 보이는 가운데 오늘 투자자들이 주목할 만한 주식들은 다음과 같다. 알리바바, 어플라이드 머티어리얼즈, 스펙트럼 브랜즈, 데스페르가닷컴 및 RLX 테크놀로지

금요일 주목해야 할 주식: 알리바바, AMAT, 스펙트럼 브랜즈, 데스페르가닷컴 및 RLX 테크놀로지

Despegar.com Corp

<h2 class="wp-block-heading">Pfizer's Oncology Transformation: Why This Beaten-Down Pharma Giant Is Poised For A Strong Comeback</h2>
Despite trading near decade-low valuations, Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen acquisition. While the market remains fixated on COVID-related revenue declines and upcoming patent cliffs, investors are overlooking the company's dramatically expanded oncology pipeline, robust free cash flow, and the potential for multiple catalysts in 2025-2026 that could drive significant share price appreciation.
<h2 class="wp-block-heading"><a>Key Points:</a></h2>
<ol class="wp-block-list">
<li>Pfizer's current valuation metrics reveal a striking disconnect with its long-term growth potential</li>
<li>The $43 billion Seagen acquisition has fundamentally transformed Pfizer's oncology pipeline</li>
<li>Despite near-term revenue pressures, Pfizer's financial position remains strong with multiple pathways to growth</li>
<li>A comparison with key competitors shows Pfizer offers compelling risk-reward at current prices</li>
<li>Upcoming catalysts in 2025-2026 could trigger significant revaluation</li>
</ol>
<h2 class="wp-block-heading"><a>Introduction: The Fall From Grace</a></h2>
Few pharmaceutical giants have experienced as dramatic a fall from grace as Pfizer. After riding high on the success of its COVID-19 vaccine and antiviral treatments in 2021-2022, the company has seen its stock price plummet over 60% from its December 2021 high of $52.61. At its current price of approximately $23.87, Pfizer trades at a P/E ratio of just 7.41, a level typically reserved for companies facing existential threats rather than one of the world's premier pharmaceutical innovators.
The market narrative surrounding Pfizer has been overwhelmingly negative, focused on:
<ol class="wp-block-list">
<li>The rapid decline of COVID-19 product revenues</li>
<li>Upcoming patent expirations for key drugs like Inlyta (2025) and Xtandi (2027)</li>
<li>Underwhelming pipeline developments in areas like weight loss</li>
<li>Concerns about the return on investment from the $43 billion Seagen acquisition</li>
</ol>
This pessimistic outlook has created what I believe is one of the most compelling investment opportunities in the pharmaceutical sector today. The market is dramatically undervaluing Pfizer's strategic transformation and the potential of its expanded oncology portfolio.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="975" height="609" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15031106/image-3.png" alt="" class="wp-image-12977" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15031106/image-3.png 975w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15031106/image-3-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15031106/image-3-768x480.png 768w" sizes="(max-width: 975px) 100vw, 975px" /></figure>
<h2 class="wp-block-heading"></h2>
<h2 class="wp-block-heading">&nbsp;Valuation Disconnect: A Market Overreaction</h2>
Pfizer's current valuation metrics tell a compelling story of market overreaction:
<ul class="wp-block-list">
<li>P/E Ratio: 7.41x (vs. industry average of ~15x)</li>
<li>Forward P/E: 8.0x (based on 2025 guidance)</li>
<li>Dividend Yield: 7.20% (substantially higher than its historical average)</li>
<li>Market Cap: $135.38 billion (down from over $300 billion at its peak)</li>
</ul>
When a company of Pfizer's caliber trades at these valuation levels, either the market is correctly anticipating a permanent deterioration in business fundamentals, or it's presenting a significant opportunity for contrarian investors. I believe it's the latter.
While Pfizer's revenue and earnings did experience a sharp decline following the normalization of COVID-19 product demand, the company's 2025 guidance suggests stabilization is at hand. For 2025, Pfizer projects:
<ul class="wp-block-list">
<li>Revenue between $61-64 billion</li>
<li>Adjusted EPS of $2.80-3.00</li>
<li>Operational revenue growth of 0-5% (excluding non-recurring COVID revenue)</li>
</ul>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="975" height="609" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033015/image-4.png" alt="" class="wp-image-12979" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033015/image-4.png 975w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033015/image-4-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033015/image-4-768x480.png 768w" sizes="(max-width: 975px) 100vw, 975px" /></figure>
These projections, while not spectacular, hardly justify a valuation typically reserved for businesses in secular decline. More importantly, they provide a stable foundation from which Pfizer's oncology transformation can drive future growth.
<h2 class="wp-block-heading"><a>The Seagen Acquisition: A Pipeline Revolution</a></h2>
In December 2023, Pfizer completed its $43 billion acquisition of Seagen, a move that fundamentally transformed the company's oncology portfolio. This acquisition wasn't merely about adding incremental revenue; it represented a strategic pivot that doubled Pfizer's early-stage oncology pipeline and positioned the company as a leader in antibody-drug conjugate (ADC) technology—one of the most promising approaches in cancer treatment today.
The Seagen acquisition brought immediate and long-term benefits:
Immediate Portfolio Enhancement:
<ul class="wp-block-list">
<li>Four FDA-approved cancer drugs (Adcetris, Padcev, Tivdak, and Tukysa)</li>
<li>Combined revenues of approximately $2.2 billion in 2023</li>
<li>Pfizer projects these medicines could contribute over $10 billion in risk-adjusted revenues by 2030</li>
</ul>
Pipeline Transformation:
<ul class="wp-block-list">
<li>Doubled Pfizer's oncology pipeline to 60 programs</li>
<li>Expanded ADC technology platform</li>
<li>Added multiple late-stage pipeline candidates with blockbuster potential</li>
</ul>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="975" height="609" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033102/image-5.png" alt="" class="wp-image-12980" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033102/image-5.png 975w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033102/image-5-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033102/image-5-768x480.png 768w" sizes="(max-width: 975px) 100vw, 975px" /></figure>
This acquisition wasn't made out of desperation but from a position of strategic foresight. ADC technology, which Seagen pioneered, allows for more precise targeting of cancer cells while sparing healthy tissue. This approach is increasingly seen as the future of cancer treatment, with the global ADC market projected to grow at a CAGR of over 10% through 2030.
Pfizer CEO Albert Bourla's comment that "We are not acquiring the golden eggs. We are acquiring the goose that laid the golden eggs" captures the strategic rationale perfectly. The long-term value lies not just in current products but in Seagen's innovation engine.
<h2 class="wp-block-heading"><a>Financial Strength Despite Headwinds</a></h2>
While near-term revenue pressures are real, Pfizer's financial position remains remarkably strong:
Q1 2025 Performance:
<ul class="wp-block-list">
<li>Revenue of $13.72 billion</li>
<li>Adjusted EPS of $0.92 (significantly above analyst expectations of $0.66)</li>
<li>Maintained full-year guidance despite external challenges</li>
</ul>
Balance Sheet Strength:
<ul class="wp-block-list">
<li>Substantial cash flow generation</li>
<li>Dividend well-covered by earnings</li>
<li>Continued cost optimization (targeting $7.7 billion in savings by 2027)</li>
</ul>
In its Q1 2025 earnings call, Pfizer's management noted they are "trending towards the upper end" of their adjusted EPS guidance range for 2025, suggesting operational efficiency and cost discipline are bearing fruit.
<h2 class="wp-block-heading"><a>Competitive Landscape: How Pfizer Stacks Up</a></h2>
To fully appreciate Pfizer's investment potential, we need to compare it to major competitors:
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="975" height="609" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033126/image-6.png" alt="" class="wp-image-12981" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033126/image-6.png 975w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033126/image-6-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033126/image-6-768x480.png 768w" sizes="(max-width: 975px) 100vw, 975px" /></figure>
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>):
<ul class="wp-block-list">
<li>Market Cap: ~$395 billion</li>
<li>P/E Ratio: ~25x</li>
<li>Dividend Yield: ~3.0%</li>
<li>Growth Challenges: Facing Stelara patent expiration in 2025 and ongoing talc litigation</li>
</ul>
Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>):
<ul class="wp-block-list">
<li>Market Cap: ~$208 billion</li>
<li>P/E Ratio: ~16x</li>
<li>Dividend Yield: ~2.9%</li>
<li>Growth Challenges: Heavy reliance on Keytruda, which faces patent expiration later this decade</li>
</ul>
AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>):
<ul class="wp-block-list">
<li>Market Cap: ~$340 billion</li>
<li>P/E Ratio: ~20x</li>
<li>Dividend Yield: ~3.6%</li>
<li>Growth Challenges: Recovering from Humira patent cliff through Skyrizi and Rinvoq growth</li>
</ul>
Compared to these peers, Pfizer offers significantly more attractive valuation metrics while facing similar industry-wide challenges. The valuation gap implies the market believes Pfizer's growth prospects are substantially worse than its competitors, an assumption not supported by the company's pipeline and strategic initiatives.
<h2 class="wp-block-heading"><a>Catalysts for Revaluation in 2025-2026</a></h2>
Several potential catalysts could drive a significant revaluation of Pfizer in the next 12-24 months:
<ol class="wp-block-list">
<li>Pipeline Milestones: Multiple late-stage readouts, particularly from oncology programs, are expected in 2025-2026, including data from the promising disitamab vedotin program for bladder cancer.</li>
<li>Margin Expansion: Pfizer's cost optimization initiatives are projected to deliver $7.7 billion in savings by 2027, potentially lifting adjusted operating margins.</li>
<li>Oncology Revenue Growth: The oncology portfolio, particularly the former Seagen products, is projected to deliver strong growth as new indications are approved and commercial execution improves.</li>
<li>GLP-1 Program Advancement: Progress with danuglipron, Pfizer's oral GLP-1 candidate, could position the company in the rapidly growing obesity market.</li>
<li>Potential Divestments or Spin-offs: Strategic portfolio optimization could unlock shareholder value, with non-core assets potentially being divested.</li>
</ol>
<h2 class="wp-block-heading"><a>Investment Risks</a></h2>
No investment thesis is complete without acknowledging risks:
<ol class="wp-block-list">
<li>Patent Cliff Pressures: Pfizer faces patent expirations for Inlyta (2025) and Xtandi (2027), which will impact revenue in the near term.</li>
<li>Seagen Integration Challenges: Realizing the full potential of the Seagen acquisition depends on successful integration and pipeline execution.</li>
<li>Pharmaceutical Pricing Pressure: The Inflation Reduction Act and potential future drug pricing reforms could impact profitability.</li>
<li>Competition in Oncology: The oncology space is highly competitive, with many companies pursuing similar targets.</li>
<li>Tariff Uncertainties: As noted in recent earnings calls, potential pharmaceutical tariffs create uncertainty.</li>
</ol>
However, at current valuation levels, much of this risk appears to be already priced into the stock, creating an asymmetric risk-reward profile.
<h2 class="wp-block-heading">Conclusion: The Case for Pfizer's Resurgence</h2>
Pfizer's dramatic fall from grace has created a compelling opportunity for patient investors. The company's strategic pivot to oncology, particularly through the Seagen acquisition, has positioned it at the forefront of one of the most promising areas in medicine. While near-term challenges are real, the current valuation reflects an overly pessimistic view that fails to account for Pfizer's pipeline potential and strategic transformation.
With multiple catalysts on the horizon and a dividend yield providing substantial income while waiting for the investment thesis to play out, Pfizer offers one of the most attractive risk-reward profiles in the pharmaceutical sector today.
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare opportunity to acquire a premier pharmaceutical innovator at a deep discount to its intrinsic value.

Biotech

Equities

Long Ideas

Opinion

ABBV

Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025

WIIM

UnitedHealth shares are trading lower amid reports indicating the company is under investigation by the US Department of Justice for possible Medicare fraud. The company said it has not been notified by the Department of Justice of the supposed criminal investigation reported.

JMP Securities analyst Andrew Boone reiterates Ibotta (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) with a Market Outperform and maintains $58 price target.

Price Target

Reiteration

Analyst Ratings

IBTA

JMP Securities Reiterates Market Outperform on Ibotta, Maintains $58 Price Target

Security National Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNFCA#NASDAQ">SNFCA</a>) reported quarterly earnings of $0.18 per share. This is a 41.94 percent decrease over earnings of $0.31 per share from the same period last year. The company reported $82.74 million in sales this quarter. This is a 1.91 percent increase over sales of $81.19 million the same period last year.

SNFCA

Security National Finl Q1 EPS $0.18 Down From $0.31 YoY, Sales $82.74M Up From $81.19M YoY

Evofem Biosciences (OTC:<a class="ticker" href="https://www.benzinga.com/stock/EVFM#OTC">EVFM</a>) reported $845.00 thousand in sales this quarter. This is a 76.55 percent decrease over sales of $3.60 million the same period last year.

EVFM

Evofem Biosciences Q1 Sales $845.00K Down From $3.60M YoY

KBC Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KBCSY#OTC">KBCSY</a>) reported quarterly earnings of $0.69 per share which missed the analyst consensus estimate of $2.28 by 69.74 percent. This is a 11.29 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $3.06 billion which beat the analyst consensus estimate of $2.90 billion by 5.60 percent. This is a 4.22 percent increase over sales of $2.94 billion the same period last year.

Earnings Beats

Earnings Misses

KBCSY

KBC Group Q1 EPS $0.69 Misses $2.28 Estimate, Sales $3.06B Beat $2.90B Estimate

JMP Securities analyst Patrick Walravens reiterates Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Market Outperform and maintains $64 price target.

GLBE

JMP Securities Reiterates Market Outperform on Global E Online, Maintains $64 Price Target

RCAT

RCAT stock has given up its prior loss. Red Cat Holdings shares were trading lower after the company reported worse-than-expected Q1 financial results.

TIC stock has given up its prior gain. Acuren shares were trading higher after the company announced a merger with NV. Also, the company announced it has been approved for uplisting to the NYSE.

Sylogist (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SYZ#TSX">SYZ</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.08 by 150 percent. This is a 81.82 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $16.32 million which missed the analyst consensus estimate of $16.34 million by 0.11 percent. This is a 0.10 percent increase over sales of $16.31 million the same period last year.

TSX:SYZ

Sylogist Q1 GAAP EPS $(0.04) Misses $0.08 Estimate, Sales $16.32M Miss $16.34M Estimate

Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) shares are rising on the heels of the company&#8217;s better-than-expected quarterly results. Several analysts raised price targets following the report. Here&#8217;s a look at <a href="https://www.benzinga.com/news/earnings/25/05/45422303/cisco-shares-climb-after-q3-eps-revenue-beat-estimates-details">what&#8217;s going on</a>.
What To Know: Cisco reported fiscal third-quarter results that came in above analyst expectations. The company said it&#8217;s seeing &#8220;clear demand&#8221; for its technologies driven by momentum with AI, which is being fueled by its secure networking portfolio and global partnerships. 
<ul class="wp-block-list">
<li>Q3 Revenue: $14.15 billion, versus estimates of $14.08 billion</li>
</ul>
<ul class="wp-block-list">
<li>Q3 Adjusted EPS: 96 cents, versus estimates of 92 cents</li>
</ul>
&#8220;Another quarter of solid execution in&nbsp;Q3&nbsp;drove revenue, margins and EPS above our&nbsp;guidance&nbsp;ranges. Our innovation positions us well for future growth and our operational discipline is generating strong cash flows, enabling us to deliver significant shareholder returns,&#8221; said&nbsp;Scott Herren, CFO of Cisco. 
Cisco guided for fourth-quarter revenue of $14.5 billion to $14.7 billion versus estimates of $14.58 billion, and adjusted earnings of 96 cents to 98 cents per share versus estimates of 95 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Cisco also raised its full-year revenue guidance from a range of $56 to $56.5 billion to a new range of $56.5 to $57 billion, and bumped up its full-year adjusted earnings forecast from $3.68 to $3.74 to a new range of $3.77 to $3.79. Analysts are anticipating full-year revenue of $56.47 billion and full-year adjusted earnings of $3.73 per share. 
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/05/45430485/cisco-is-targeting-a-multi-billion-dollar-security-shake-up-and-it-starts-with-killing-the-firewall">Cisco Is Targeting A Multi-Billion-Dollar Security Shake-Up—And It Starts With Killing The Firewall</a>
Analyst Changes: Following the print, multiple analysts lifted price targets on the stock. 
<ul class="wp-block-list">
<li>Wells Fargo analyst Aaron Rakers upgraded Cisco from Equal-Weight to <a href="https://www.benzinga.com/analyst-stock-ratings">Overweight</a> and raised the price target from&nbsp;$72&nbsp;to&nbsp;$75.</li>
</ul>
<ul class="wp-block-list">
<li>Rosenblatt analyst Mike Genovese maintained a Buy rating and raised the price target from&nbsp;$63&nbsp;to&nbsp;$74.</li>
</ul>
<ul class="wp-block-list">
<li>JPMorgan analyst Samik Chatterjee maintained an Overweight rating and raised the price target from&nbsp;$70&nbsp;to&nbsp;$73.</li>
</ul>
<ul class="wp-block-list">
<li>Barclays analyst Tim Long maintained an Equal-Weight rating and raised the price target from&nbsp;$61&nbsp;to&nbsp;$66.</li>
</ul>
CSCO Price Action: <a href="http://benzinga.com/quote/csco">Cisco shares</a> are up year-to-date, but are still trading below 52-week highs of $66.50 reached in February. The stock was up 5.39% at $64.60 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">Tariffs Slow Retail Spending As Producer Prices Post Sharpest Drop Since 2020</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/MacroEcon">MacroEcon</a>/Shutterstock.

Guidance

Movers

CSCO

Cisco Systems Stock Is Rising Thursday: What's Fueling The Move?

UBS analyst Kevin Caliendo maintains ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) with a Neutral and lowers the price target from $16 to $10.

ZIMV

UBS Maintains Neutral on ZimVie, Lowers Price Target to $10

JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) with a Market Outperform and maintains $9 price target.

FHTX

JMP Securities Reiterates Market Outperform on Foghorn Therapeutics, Maintains $9 Price Target

UBS analyst Alberto Valerio maintains Controladora Vuela (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) with a Buy and lowers the price target from $12 to $6.

VLRS

UBS Maintains Buy on Controladora Vuela, Lowers Price Target to $6

New Fortress Energy Shares Resume Trade

UBS analyst Shneur Gershuni maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Buy and lowers the price target from $259 to $228.

TRGP

UBS Maintains Buy on Targa Resources, Lowers Price Target to $228

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently rotating near our 585.75 reference level. For buyers to maintain control, we&#8217;d like to see price move up to 587.31 and establish that level as a support base. Should bulls remain dominant, the next upside objective is 589.71. Holding 589.71 during regular trading could open the door to a further move toward 592.00. If momentum remains on the buyers&#8217; side, the high bull objective for the day is marked at 593.73.&nbsp;
If 585.75 loses footing as a support area, we'll be watching 584.68 as the next key level to monitor. If pressure builds and sellers stay active, the downside may extend to 583.18. A breakdown beneath that could lead to further weakness toward 581.97. Should sentiment shift dramatically to the downside, the low bear objective on the day stands at 580.67.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is currently hovering near our level of 516.58. Bulls need to gain ground above 517.97 and solidify that area as a stable base. A firm hold could lead to a challenge of 518.65, and if strength persists, 519.87 may come into play. Should buyers stay aggressive, we anticipate a possible extension to 521.15. The top-side goal for bulls today is set at 522.57.&nbsp;
If the auction struggles to stay buoyant above 516.58, sellers may drive the price toward 515.00. Breaking below that level could invite further downside exploration to 513.64. A sustained bearish session may bring 511.53 into play, and if that floor fails to hold, we are targeting 509.87 as the session's lower bear target.
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
Apple is trading close to our level of 209.81. If bulls want to take charge, they'll need to secure 211.12 and convert it into a platform for higher prices. Holding that zone may propel the stock toward 212.44. Continued strength in the name could push price to 214.07, with the high-side bull objective standing at 215.25.&nbsp;
Should 209.81 fall through, we'll look to 208.81 for initial support. If sellers persist, a test of 207.93 could follow. Continued downward action may lead to 207.18 being probed, and if pressure intensifies further, our low bear target sits at 206.55.
Microsoft Corp. (MSFT)
Microsoft is currently trading near 450.26. If bulls are able to hold this area and drive price higher, the next upside target is 453.02. A clean move above and hold of this level during market hours could bring 455.77 into view. If bullish energy sustains, the upper boundary we're eyeing for today is 457.25.&nbsp;
On the downside, if 450.26 can't hold up, expect bears to aim for 448.18. A breakdown there could see the stock testing 446.33, with pressure building into 444.95 if sellers stay committed. Should the auction extend to deeper lows, the low bear target is marked at 442.95.
NVIDIA Corporation (NVDA)
NVIDIA is actively trading near 134.56. A bullish continuation would require price to push above 135.64 and turn it into a support floor. If that transition occurs, look for 136.98 to be challenged next. A healthy bid could bring price action to 137.94, with bulls aiming for a top-side target at 138.55.&nbsp;
If the bulls can't keep 134.56 intact, we expect the bears to pressure the stock lower toward 133.31. Failing that level could invite sellers to test 132.19. If momentum remains with the bears, 131.42 could be visited, and the session's low-side bear target is placed at 129.53.
Alphabet Inc Class A (GOOGL)
Alphabet is currently auctioning near 163.79. For bulls to stay in control, they need to establish 165.41 as a solid base and push toward 167.04. A sustained rally today could push price toward our upside objective of 169.34.&nbsp;
If 163.79 fails to act as support, the next area of interest lies at 161.79. A break below there may see the auction retreat to 160.36. Continued weakness could send the name down to our low-end target of 158.54.
Meta Platforms Inc (META)
Meta is auctioning near our level of 650.56. Bulls will want to maintain strength above this area and attempt a move to 655.54. If the momentum holds, the price may rally to 658.86. Should buyers remain in control, our high bull target of 663.33 becomes the key upside marker.&nbsp;
Should 650.56 give out, the first line of defense for the bulls is at 646.48. Selling pressure below that level could drag the price down to 642.59. If sellers remain dominant, the lower target for the day is 635.49.
Tesla Inc. (TSLA)
Tesla is currently revolving around 340.97. For a bullish day, price needs to climb toward 346.64 and hold it as firm support. If momentum follows through, the next step is 350.87. With sustained buying, 356.80 becomes the next potential area of interest. The bullish stretch target sits at 363.84.&nbsp;
If 340.97 doesn't hold, we'll be eyeing 333.93 as the next level under pressure. A breakdown through that opens the path to 327.59. If selling intensifies, 322.52 becomes the likely bear target to the downside.
Final Word:&nbsp;
Today's session is packed with market-moving data. At 8:30AM ET, we'll see the release of April's PPI Final Demand along with Initial and Continuing Jobless Claims. Also hitting the tape at that time are the Philly Fed Manufacturing Index and Empire State Manufacturing Survey—both key sentiment indicators. At 9:15AM ET, attention shifts to Industrial Production, Capacity Utilization, and Manufacturing Output, all offering a deeper look into real economic activity. At 10AM ET, housing data comes into focus with the NAHB Housing Market Index.&nbsp;
Fed commentary also plays a major role today, with Chair Jerome Powell scheduled to speak at 8:40AM ET, followed by remarks from FOMC's Barr at 2:05PM ET. With inflation, labor, manufacturing, and housing data all hitting at once, combined with Fed commentary, the market may experience heightened volatility. Stay sharp, manage your risk, and be ready to adapt as the data unfolds.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Technicals

Signals

AAPL

How To Trade SPY, Tech After Biggest Monthly PPI Drop Since Covid

UBS analyst Dennis Geiger maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Neutral and lowers the price target from $44 to $27.

JACK

UBS Maintains Neutral on Jack In The Box, Lowers Price Target to $27

JMP Securities analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and maintains $20 price target.

BNTC

JMP Securities Reiterates Market Outperform on Benitec Biopharma, Maintains $20 Price Target

"Stay buckled. It's just a question of whether the airbags come out now,"&nbsp; Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) chief Harvey Schwartz told <a href="https://www.bloomberg.com/news/videos/2025-04-17/bloomberg-open-interest-04-17-2025-video">Bloomberg</a> in an interview on April 17. While tariffs have turned&nbsp; jetliners around mid-air and slowed parcel traffic, Schwartz insists the real hazard is the uncertainty most observers cannot see.
His warning landed as the U.S. and China traded blows that lifted some levies to 145% and stretched supply chains well beyond breaking points for some manufacturers.
Don't Miss:
<ul class="wp-block-list">
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
<h2 class="wp-block-heading">Buckle Up For Whiplash</h2>
The trade scuffle's first casualty was aviation. Reuters reported that a<a href="https://www.reuters.com/business/aerospace-defense/boeing-jet-returns-us-china-victim-trumps-tariff-war-2025-04-20/"> $55 million Boeing 737 MAX</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) painted for Xiamen Airlines left Renton, Washington, on April 18 but returned to Seattle the next evening after a 125% duty made the deal financially unviable for the Chinese carrier.
On April 20, <a href="https://www.dhl.com/discover/en-sg/news/important-announcement-shipping-to-us">DHL said</a> it would halt business-to-consumer shipments over $800 to the U.S. due to new customs rules, effective April 21. Delays hit lower-value parcels too. After discussions with U.S. authorities,<a href="https://www.dhl.com/us-en/home/important-information/2025/shipments-to-the-united-states-with-a-customs-value-exceeding-usd-800.html"> DHL resumed shipments </a>soon after, following adjustments that eased processing of higher-value entries.
Policymakers see the stress, too. On April 22, the <a href="https://mediacenter.imf.org/news/imf-world-economic-outlook-presser/s/33be8aaf-2578-4d8f-a8fd-ae7f5516ad3f">International Monetary Fund</a> released its updated World Economic Outlook, lowering its 2025 global growth forecast to 2.8%—a 0.5 percentage point decrease from January.
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
IMF Chief Economist Pierre-Olivier Gourinchas <a href="https://www.youtube.com/watch?v=uXT-vsT1qxo">said</a> global trade growth could be "more than halved" to 1.7% in 2025 if tariffs persist. He also said the U.S. growth forecast was trimmed to 1.8%, citing heightened uncertainty.
History shows why the C-suite are skittish. The tariff volley that began in 2018 lopped roughly <a href="https://ers.usda.gov/sites/default/files/_laserfiche/publications/102980/ERR-304.pdf?v=13480#:~:text=From%20mid%2D2018%20to%20the,occurring%20for%20exports%20to%20China.">$1.7 billion </a>off U.S. quarterly farm exports within months—a reminder of how friction can slice revenue.&nbsp;
The S&amp;P 500 experienced significant intraday volatility on April 8. The index surged by 4.1% in early trading, only to reverse course and decline by 3% later in the day, closing down 1.6%.
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.&nbsp;
In a separate <a href="https://www.youtube.com/watch?v=PC5_6RHwc-U">Bloomberg</a> interview, Schwartz emphasized that while a recession is &#8220;certainly on the table,&#8221; it&#8217;s premature to make a definitive judgment. He highlighted that the primary concern isn&#8217;t just the tariffs themselves but the pervasive uncertainty they introduce, which stalls decision-making and chills economic activity.&nbsp;
Schwartz said that CEOs are shifting from growth strategies to contingency planning amid the volatility.&nbsp;
He stressed the importance of the U.S. and China finding a cooperative equilibrium to stabilize global trade, warning that prolonged tensions could have far-reaching implications beyond immediate market disruptions.
Read Next:
<ul class="wp-block-list">
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Carlyle CEO Harvey Schwartz Says 'Stay Buckled' Amid Market Turmoil – 'It's Just A Question Of Whether The Airbags Come Out

Press Releases

Despegar.com to Announce Third Quarter 2024 Financial Results on November 14, 2024

Despegar.com Announces 3Q24 Financial Results

Contracts

L Catterton Latin America Makes Strategic Investment in WeVets

Despegar.com Enters Into Merger Agreement to Be Acquired by Prosus for $19.50 Per Share in Cash

Prosus to Acquire Latin America's Leading Online Travel Agency, Despegar, for US$1.7bn

Shareholder Alert: Ademi LLP investigates whether Despegar.com, Corp. is obtaining a Fair Price for its Public Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Despegar.com, Corp. - DESP

Despegar and HBX Group Enter Into a Strategic Partnership

Despegar.com Announces 4Q24 and FY24 Financial Results

Prosus and Despegar Complete Acquisition

Airbnb

Atour Lifestyle Holdings Limited - American Depositary Shares

Atour Lifestyle Holdings

Booking Holdings

Choice Hotels International, Inc. Common Stock

Choice Hotels Intl

Expedia Group

Global Business Travel Group, Inc. Class A Common Stock

Global Business Travel

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Gr

Hyatt Hotels Corporation Class A Common Stock

Hyatt Hotels

Hilton Grand Vacations

Hilton Worldwide Holdings Inc. Common Stock

Hilton Worldwide Holdings

H World Group Limited - American Depositary Shares

H World Group

Intercontinental Hotels Group American Depositary Shares (Each representing one Ordinary Share)

Comments

Despegar.com

뉴스

파트너 / 기고자

벤징가 글로벌